De novo and recurrent malignancy.

Area of Science:

• Hepatology
• Transplantation Medicine
• Oncology

Background:

• Malignancy is a major cause of death post-liver transplant.
• Cancer can arise from recipient recurrence, donor transmission, or de novo development.
• Current screening and management protocols are suboptimal, leading to late-stage diagnoses.

Purpose of the Study:

• To review current guidelines for screening liver transplant donors and recipients for malignancy.
• To summarize management strategies for de novo cancers post-liver transplant.
• To highlight areas for improvement in pre- and post-transplant cancer surveillance.

Main Methods:

• Literature review of current recommendations and guidelines.
• Synthesis of evidence on donor and recipient screening.
• Analysis of management approaches for post-transplant malignancies.

Main Results:

• Individualized assessment for listing patients with prior malignancy is standard.
• Screening guidelines often rely on general population data, lacking specificity for transplant candidates.
• The impact of immunosuppression on de novo cancer development requires further investigation.

Conclusions:

• There is a critical need for updated, transplant-specific screening guidelines for donors and recipients.
• Optimizing immunosuppression protocols may reduce de novo cancer risk.
• Improved surveillance and timely intervention are essential for better outcomes in liver transplant recipients diagnosed with cancer.